SR One Capital Management, LP
CIK 1910264 · View on SEC EDGAR ↗
- Portfolio value
- $1.0B
- Positions
- 15
- As of
- June 30, 2026
#2,393 of 9,443 by 13F value · top 25.3%
Portfolio value QoQ: +13.5% 13F does not disclose cash
- Top 10 holdings weight
- 95.11%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 11
- Effective number of positions
- 7.2
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 21.25% Est. buys $207,624,279 · sells $290,547,743
Median holding: 6.0 quarters Tracked Q4 2024–Q2 2026 · 83.3% still held
- New positions
- 3
- Increased
- 1
- Decreased
- 0
- Closed
- 2
On this page
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Sector breakdown
Healthcare
80.1%
Other/Unmapped
19.9%
Full portfolio 15 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| MANE Veradermics, Incorporated Common Stock | $295,285,652 | 28.42% | 2,401,868 | $143,607,688 | |||
| ZBIO Zenas BioPharma, Inc. - Common Stock | $127,860,735 | 12.31% | 5,037,854 | $29,370,689 | |||
| CRSP CRISPR Therapeutics AG - Common Shares | $111,194,134 | 10.70% | 2,038,763 | $14,210,178 | |||
| Unknown issuer (CUSIP: 05348Y105) | $108,920,725 | 10.48% | 3,308,649 | Up ×1 | |||
| DSGN Design Therapeutics, Inc. - Common Stock | $94,438,108 | 9.09% | 6,526,476 | $24,996,404 | |||
| Unknown issuer (CUSIP: 67613T104) | $71,002,261 | 6.83% | 3,794,883 | Up ×1 | |||
| ALMS Alumis Inc. - Common Stock | $55,151,473 | 5.31% | 1,959,896 | $11,974,964 | |||
| ORIC Oric Pharmaceuticals, Inc. - Common Stock | $49,984,609 | 4.81% | 4,615,384 | $-8,492,306 | Up ×1 | ||
| MLYS Mineralys Therapeutics, Inc. - Common Stock | $42,195,803 | 4.06% | 1,563,966 | $-172,036 | |||
| SPRY ARS Pharmaceuticals, Inc. - Common Stock | $32,143,353 | 3.09% | 4,012,903 | $-80,258 | |||
| Unknown issuer (CUSIP: 60705V103) | $26,613,365 | 2.56% | 1,986,072 | Up ×1 | |||
| NKTX Nkarta, Inc. - Common Stock | $9,433,332 | 0.91% | 3,333,333 | $2,399,999 | |||
| OCS Oculis Holding AG - Ordinary shares | $8,890,975 | 0.86% | 641,022 | $-8,153,800 | |||
| RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $4,599,573 | 0.44% | 137,753 | $1,713,648 | |||
| ENGN enGene Holdings Inc. - Common Stock | $1,293,607 | 0.12% | 747,750 | $-3,798,571 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 05348Y105) | $108,920,725 | 3,308,649 | 10.48% |
| Unknown issuer (CUSIP: 67613T104) | $71,002,261 | 3,794,883 | 6.83% |
| Unknown issuer (CUSIP: 60705V103) | $26,613,365 | 1,986,072 | 2.56% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| MANE | Price move only | +0 | +$143.6M |
| ZBIO | Price move only | +0 | +$29.4M |
| DSGN | Price move only | +0 | +$25.0M |
| CRSP | Price move only | +0 | +$14.2M |
| ALMS | Price move only | +0 | +$12.0M |
| ORIC | Bought more | +100K | -$8.5M |
| OCS | Price move only | +0 | -$8.2M |
| ENGN | Price move only | +0 | -$3.8M |
| NKTX | Price move only | +0 | +$2.4M |
| RARE | Price move only | +0 | +$1.7M |
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.